Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we focus on Revive Therapeutics, a pharmaceuticals company based out of Toronto, Canada, who is currently in Phase 3 clinical trials for its bucillamine Covid treatment, as well as developing psychedelic therapeutic solutions for aggressive breast cancer and treatment-resistant depression.
Enjoy!
